The Zydus drug recall affects 70,776 injectable vials in the US after the medicine failed impurity and degradation specifications.
Roche Q3 CEETRIS growth highlights India’s strategic importance as the company’s International region expands and demand for specialty medicines rises.
Abbott plans a nutrition spin-off by 2027 while cutting its 2026 sales growth forecast, reshaping its healthcare portfolio and growth strategy.
The FDA clears a lower-cost generic HRT patch from Zydus and approves AstraZeneca’s Ultomiris for adults with IgA nephropathy, expanding menopause care and kidney disease treatment options.
Sanofi's Qfitlia approval puts haemophilia prophylaxis in India in focus as research highlights gaps in preventive treatment.
Toripalimab's expanded use in India brings real-world evidence into focus, with a multicentre study examining treatment outcomes across PD-L1 subgroups.
Cotecna, a leading provider of Testing, Inspection and Certification (TIC) services, today announced the acquisition of Energon Labs, a cGMP-compliant, USFDA-inspected, ISO 9001:2015 and ISO 17025:2017 certified analytical testing laboratory
Eosinophilic esophagitis treatment gains a potential new option as AstraZeneca and Amgen report sustained remission and symptom improvements with Tezspire.
GSK’s Hibsago becomes the first ASO approved for chronic hepatitis B, offering patients a new treatment approach for sustained viral control.
Sun Pharma’s $355M acquisition of Unloxcyt gains momentum as the therapy earns NCCN Category 2A status for locally advanced skin cancer.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
